IL132156A0 - Neoglycoproteins - Google Patents

Neoglycoproteins

Info

Publication number
IL132156A0
IL132156A0 IL13215698A IL13215698A IL132156A0 IL 132156 A0 IL132156 A0 IL 132156A0 IL 13215698 A IL13215698 A IL 13215698A IL 13215698 A IL13215698 A IL 13215698A IL 132156 A0 IL132156 A0 IL 132156A0
Authority
IL
Israel
Prior art keywords
conjugates
polyamide
neoglycoproteins
group
macromolecular
Prior art date
Application number
IL13215698A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9802450.8A external-priority patent/GB9802450D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL132156A0 publication Critical patent/IL132156A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
    • B01J20/26—Synthetic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Polyamides (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
IL13215698A 1997-04-18 1998-04-16 Neoglycoproteins IL132156A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97810244 1997-04-18
EP97810243 1997-04-18
GBGB9802450.8A GB9802450D0 (en) 1998-02-05 1998-02-05 Organic compounds
PCT/EP1998/002227 WO1998047915A1 (en) 1997-04-18 1998-04-16 Neoglycoproteins

Publications (1)

Publication Number Publication Date
IL132156A0 true IL132156A0 (en) 2001-03-19

Family

ID=27238761

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13215698A IL132156A0 (en) 1997-04-18 1998-04-16 Neoglycoproteins

Country Status (12)

Country Link
US (2) US6399071B1 (xx)
EP (1) EP0970114B1 (xx)
JP (1) JP3474583B2 (xx)
CN (1) CN1185253C (xx)
AT (1) ATE332918T1 (xx)
AU (1) AU733282B2 (xx)
CA (1) CA2284729A1 (xx)
DE (1) DE69835201T2 (xx)
ES (1) ES2268776T3 (xx)
IL (1) IL132156A0 (xx)
PT (1) PT970114E (xx)
WO (1) WO1998047915A1 (xx)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399071B1 (en) * 1997-04-18 2002-06-04 Novartis Ag Neoglycoproteins
AU761831B2 (en) 1998-04-15 2003-06-12 Bioscience 2002 Llc Inhibition of xenoreactive antibodies
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
JP2002531531A (ja) * 1998-12-09 2002-09-24 ラ ホヤ ファーマシューティカル カンパニー 循環している抗体を減少させるための方法および処方物
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
ATE474590T1 (de) 1999-05-10 2010-08-15 Paolo Brenner Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen
WO2004043405A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
CN100365007C (zh) * 2003-09-01 2008-01-30 北京大学 三糖和五糖寡糖抗原，它们的合成方法以及在制备抑制排斥反应的药物中的用途
WO2006044577A1 (en) * 2004-10-13 2006-04-27 Ilypsa, Inc. Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle
US20060078534A1 (en) * 2004-10-13 2006-04-13 Dominique Charmot Toxin binding compositions
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
ES2442024T3 (es) 2008-07-15 2014-02-07 Academia Sinica Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
WO2010011284A2 (en) 2008-07-21 2010-01-28 The Brigham And Women's Hospital, Inc. Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
AU2013306098A1 (en) 2012-08-18 2015-02-12 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US10086054B2 (en) * 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
WO2015007326A1 (en) 2013-07-18 2015-01-22 Institut D'investigació Biomèdica De Bellvitge (Idibell) Agents comprising a terminal alpha-galactosyl moiety for use in prevention and/or treatment of inflammatory diseases
JP6486368B2 (ja) 2013-09-06 2019-03-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
US9982041B2 (en) 2014-01-16 2018-05-29 Academia Sinica Compositions and methods for treatment and detection of cancers
KR20160132034A (ko) 2014-03-13 2016-11-16 우니페르시테트 바젤 미엘린-관련 당단백질에 대한 IgM 항체와 결합하는 탄수화물 리간드
EP3129767B1 (en) 2014-03-27 2021-09-01 Academia Sinica Reactive labelling compounds and uses thereof
JP2017521645A (ja) * 2014-05-15 2017-08-03 メイヨ フォンデーシヨン フォー メディカル エジュケーション アンド リサーチ 放射性金属のサイクロトロン生成用の溶液ターゲット
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CN106661099A (zh) 2014-05-27 2017-05-10 中央研究院 抗her2醣抗体及其用途
CA2950423A1 (en) 2014-05-27 2015-12-03 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
WO2015184001A1 (en) 2014-05-28 2015-12-03 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
EP2987503A1 (en) * 2014-08-22 2016-02-24 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Methods and reagents for prevention and/or treatment of infection
KR102422375B1 (ko) 2014-09-08 2022-07-18 아카데미아 시니카 당지질을 사용한 인간 iNKT 세포 활성화
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
AU2015378564A1 (en) 2015-01-24 2017-07-13 Academia Sinica Novel glycan conjugates and methods of use thereof
US11091591B2 (en) 2015-09-16 2021-08-17 Universität Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
JP2019515876A (ja) 2016-03-08 2019-06-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｎ−グリカンおよびそのアレイのモジュール合成のための方法
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
BR112019019145A2 (pt) * 2017-03-15 2020-04-14 Polyneuron Pharmaceuticals Ag proteínas de ligação a carboidrato sequestrante de glicopolímeros
EP3964235A1 (en) 2020-09-08 2022-03-09 RemAb Therapeutics SL Glycoconjugates and medical uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149425A (en) * 1988-11-09 1992-09-22 Chembiomed, Ltd. Affinity supports for hemoperfusion
US5286846A (en) * 1991-06-14 1994-02-15 The Government Of The United States Of America As Represented By The Dept. Of Health And Human Services Amino acid derivative and bromoacetyl modified peptides for the preparation of synthetic peptide polymers, conjugated peptides, and cyclic peptides
ATE232730T1 (de) * 1991-08-23 2003-03-15 Alberta Res Council Verfahren und zusammensetzungen zur verhinderung der antikörper-vermittelten abstossung von xenogenen transplantaten
EP0601417A3 (de) * 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
FR2727117A1 (fr) 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
WO1997019105A1 (en) 1995-11-21 1997-05-29 Novartis Ag Multivalent polymers, processes for their preparation, and their use for preparing biologically active compounds.
US6399071B1 (en) * 1997-04-18 2002-06-04 Novartis Ag Neoglycoproteins

Also Published As

Publication number Publication date
AU733282B2 (en) 2001-05-10
DE69835201D1 (en) 2006-08-24
US20020164347A1 (en) 2002-11-07
CA2284729A1 (en) 1998-10-29
CN1252807A (zh) 2000-05-10
CN1185253C (zh) 2005-01-19
JP3474583B2 (ja) 2003-12-08
EP0970114B1 (en) 2006-07-12
US6399071B1 (en) 2002-06-04
AU7643998A (en) 1998-11-13
ES2268776T3 (es) 2007-03-16
US6723831B2 (en) 2004-04-20
DE69835201T2 (de) 2007-06-14
JP2001500528A (ja) 2001-01-16
ATE332918T1 (de) 2006-08-15
WO1998047915A1 (en) 1998-10-29
EP0970114A1 (en) 2000-01-12
PT970114E (pt) 2006-12-29

Similar Documents

Publication Publication Date Title
IL132156A0 (en) Neoglycoproteins
AP9801392A0 (en) Concentrated antibody preparation.
HUP9900605A3 (en) Lipopolyamines as transfection agents, preparation and use thereof and pharmaceutical compositions containing them
HK1028594A1 (en) Adamantane derivatives
IL136369A0 (en) Adamantane derivatives
CZ20012028A3 (cs) Nové N-substituované 2-kyanopyrrolidiny, farmaceutický prostředek, který je obsahuje a jejich použití jako léčivo
BR9507999A (pt) Conjugado biologicamente ativo composto substancialmente purificado polimero solúvel em água e composição farmacêutica
HUP0100507A3 (en) Polyethylene glycol-grf conjugates, site-specific preparation thereof, pharmaceutical compositions comprising thereof and their use
MY129356A (en) Electrospun pharmaceutical compositions
CY2424B1 (en) Pharmaceutical composition for use in treatment ofdiabetes.
EP0841936A4 (en) CONJUGATION-STABILIZED THERAPEUTIC AGENT COMPOSITIONS, ADDITIONAL FORMULATIONS AND DIAGNOSTICS
HUP0200308A2 (en) Quinolinecarboxamides as antiviral agents, pharmaceutical compositions containing them and their use
SE9704546D0 (sv) Novel compounds
IL136938A0 (en) 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF
HUP0204081A3 (en) 4-pyrimidinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use
HUP0203505A3 (en) 2'-substituted 1,1'-biphenyl-2-carbonamides, and pharmaceutical compositions containing said compounds
AU9018898A (en) Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments
HUP0200386A3 (en) Nitroxyderivatives having antiinflammatory, analgesic and antithrombotic activity and pharmaceutical compositions containing them and their use
HUP0203194A3 (en) Phenylpiperazines, pharmaceutical compositions containing them and their use
HUP0203735A3 (en) 4-pyridinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use
IL126714A (en) Use of cells, organs or components thereof for the preparation of a pharmaceutical composition for establishing selective immune downregulation
HK1040980A1 (zh) 聯苯磺酰基氨基氰、其製備方法及其作為藥物的用途
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
HUP0104834A3 (en) Sulphonyloxazolamines, their use, pharmaceutical compositions containing them and their preparation
GB9811221D0 (en) Bacterial-pheromones and uses therefor